邁克生物(300463.SZ):擬終止經營並解散邁凱基因
格隆匯12月13日丨邁克生物(300463.SZ)公佈,2017年4月28日,公司與德國凱傑QIAGEN N.V.(“德國凱傑”)簽署《關於共同設立邁凱基因生物科技有限公司之合資經營協議》(“《合資經營協議》”),雙方將在中國共同投資設立邁凱基因生物科技有限公司(“邁凱基因”或“合資公司”),旨在中國就下一代測序技術(“NGS”)及產品進行本地化開發、生產、組裝、獲取食藥監局批准和銷售,為客户提供從樣本製備到結果解讀的完整二代測序解決方案,並持續開發和商業化未來NGS產品。邁凱基因註冊資本3000萬美元,其中公司出資1800萬美元佔其註冊資本的60%,德國凱傑出資1200萬美元佔其註冊資本的40%。
邁凱基因自設立以來其經營活動主要圍繞GeneReader產品的註冊以及多項基因測序試劑盒研發展開,由於對有關產品技術轉移和長期工作計劃無法達成一致,合作雙方決定提前解除《合資經營協議》。2019年12月12日,經邁凱基因全體董事一致同意,做出終止經營並解散合資公司的決議。雙方股東將委派代表成立清算小組,按照有關法律法規和合資公司《公司章程》開展後續工作。
上述投資旨在開發和製造適用於臨牀檢測的基因測序產品,為公司在精準醫療領域的遠期戰略佈局,該投資項目的終止,不影響公司在分子診斷技術平台下的其他研發項目推進。截止2018年年末,邁凱基因實收資本為1800萬美元,淨資產為約1.01億人民幣,累計虧損1978.52萬人民幣,2019年前三季度虧損817.67萬人民幣。以上財務數據已按股東權益計入公司合併報表中,此次投資的終止對公司帶來的整體財務影響將視邁凱基因最終清算情況而定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.